AstraZeneca’s newly approved pill fails frontline breast cancer study
Published . Updated .
Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
Directly affected
Indirectly affected
- INSW International Seaways
Tanker operators earn more when freight rates spike
- DHT DHT Holdings
Tanker operators earn more when freight rates spike
- TNK Teekay Tankers
Tanker operators earn more when freight rates spike
- ZIM ZIM Integrated Shipping
Container lines are exposed when a shipping lane is disrupted
- MATX Matson
Container lines are exposed when a shipping lane is disrupted
- XOM Exxon Mobil
Oil producers earn more when crude prices rise
- CVX Chevron
Oil producers earn more when crude prices rise
- STNG Scorpio Tankers
Tanker operators earn more when freight rates spike
- DAL Delta Air Lines
Airlines pay more for fuel when oil prices jump
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
Source: BioPharma Dive
Astrazeneca (AZN) since this story, compared with the market
Since the first closing price after “AstraZeneca’s newly approved pill fails frontline breast cancer study,” Astrazeneca (AZN) is +1.35%. The S&P 500 fund (SPY) is +1.21% over the same days, a +0.14% difference versus the market.
Filings that name Astrazeneca (AZN) around 14 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Astrazeneca (AZN)
Companies mentioned with this story
- AZN Astrazeneca
For “AstraZeneca’s newly approved pill fails frontline breast cancer study,” Astrazeneca (AZN) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
- FRO Frontline
Frontline (FRO) is linked, with no stored direction, high confidence in the 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study.” Reason on file: The reported development directly names Frontline, LTD. in the headline; GA resolved that company to FRO
- ACHC Acadia Healthcare
In “AstraZeneca’s newly approved pill fails frontline breast cancer study,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “AstraZeneca’s newly approved pill fails frontline breast cancer study,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- CRDF Cardiff Oncology
Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study.” Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Astrazeneca (AZN)
The 14 Sep 2026 story “AstraZeneca’s newly approved pill fails frontline breast cancer study” names Astrazeneca (AZN) because of this story.
The link for Astrazeneca (AZN) is this: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
Frontline (FRO) is here too. Its reason reads: The reported development directly names Frontline, LTD. in the headline; GA resolved that company to FRO
Price levels for Astrazeneca (AZN)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. AZN traded between 154.83 and 169.73 across 20 sessions. The latest close on file is 164.02. FRO traded between 46.67 and 59.74 across 20 sessions. The latest close on file is 50.72.
How strong the case is around Astrazeneca (AZN)
46 out of 100
“AstraZeneca’s newly approved pill fails frontline breast cancer study” scores 46 out of 100. The score uses 1 sources, and 8 linked companies.